As of Thursday close, ChemoCentryx Inc.’s (NASDAQ:CCXI) stock was up $26.32, moving up 109.17 percent to $50.43. The average number of shares traded per day over the past five days has been 7,905,020 shares. 4 times new highs have been achieved over the past 5 days, with a $27.20 gain in that time frame. In the last twenty days, the average volume was 2,602,035, while in the previous 50 days, it was 1,763,922.
Since last month, CCXI stock rose 99.09%. Shares of the company fell to $21.74 on 07/12/22, the lowest level in the past month. A 52-week high of $42.16 was reached on 08/04/22 after having rallying from a 52-week low of $13.11. Since the beginning of this year, CCXI’s stock price has risen by 38.51% or $14.02, and marked a new high 4 times. However, the stock has increased by 19.62% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
ChemoCentryx Inc. (CCXI) last reported insider trading activity 57 days ago on Jun 09. Tyree James L, the Director of the company, disposed of 3,863 shares for $25.66 on Jun 09. It resulted in a $99,129 divestment by the insider. Tyree James L sold 37,500 shares at an average price of $35.02 on Dec 17. The insider now owns 15,275 shares following the transaction. On Oct 12, 10% Owner Vifor (International) Ltd sold 4,000,000 shares at $39.43 apiece. The transaction was valued at $157,720,000.
The stock’s beta is 1.69. Besides these, the trailing price-to-sales (P/S) ratio of 133.35, the price-to-book (PB) ratio of 13.82.
In the three months ended March 30, ChemoCentryx Inc.’s quick ratio stood at 5.10, while its current ratio was 5.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.02, and the total debt-to-equity ratio was 0.09. On the profitability front, the trailing twelve-month gross margin is 98.10% percent. Based on annual data, CCXI earned $31.92 million in gross profit and brought in $32.22 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -41.90%. Return on equity (ROE) for the past 12 months was -47.20%.
In ChemoCentryx Inc.’s quarter-end financial report for March 30, it reported total debt of $4.55 million against cash and short-term investments of $300.02 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. CCXI’s revenue fell -89.65% to $4.63 million during the quarter, while net income inched up to $10.92 million. While analysts expected ChemoCentryx Inc. to report -$0.31 quarterly earnings, the actual figure was -$0.55 per share, beating the consensus estimate by -77.40%. During the quarter, the company generated -$37.22 million in EBITDA. The liabilities of ChemoCentryx Inc. were 181.73 million at the end of its most recent quarter ended March 30, and its total debt was $73.86 million. The value of shareholders’ equity is $71.19 million.
This quick technical analysis looks at ChemoCentryx Inc.’s (CCXI) price momentum. With a historical volatility rate of 357.97%, the RSI 9-day stood at 92.04% on 04 August.
With respect to its five-day moving average, the current ChemoCentryx Inc. price is up by +117.09% percent or $27.20. At present, CCXI shares trade +100.84% above its 20-day simple moving average and +112.61% percent above its 100-day simple moving average. However, the stock is currently trading approximately +125.54% above its SMA50 and +55.50% above its SMA200.
Stochastic coefficient K was 72.83% and Stochastic coefficient D was 56.46%, while ATR was 4.24. Given the Stochastic reading of 98.38% for the 14-day period, the RSI (14) reading has been calculated as 87.55%. As of today, the MACD Oscillator reading stands at 6.27, while the 14-day reading stands at 7.42.
ChemoCentryx Inc. (CCXI) has been rated Buy by analysts. According to 0 brokerage firms, CCXI is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate ChemoCentryx Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $64.50, the current consensus forecast for the stock is $34.00 – $106.00. Based on these forecasts, analysts predict ChemoCentryx Inc. (CCXI) will achieve an average price target of $71.25.